Distributing the GOP megabill’s rural health fund will depend on a variety of metrics that will vary from year-to-year and are not easily quantifiable, like calculating a state’s progress toward policies aligned with the so-called MAHA movement, according to HHS’ notice of funding opportunity, a detailed document that some experts say outlines a subjective grading system for states seeking rural relief.

FDA will fast-track review of EMD Serono’s fertility drug in addition to drugs from eight other companies under the Commissioner’s National Priority Voucher program, which incentivizes companies to make their products more affordable and take other steps in the “national interest.”